Analysts expect that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce $44.00 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Vanda Pharmaceuticals’ earnings. Vanda Pharmaceuticals posted sales of $38.24 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The business is expected to announce its next quarterly earnings results on Wednesday, February 21st.

On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $44.00 million for the current financial year, with estimates ranging from $164.80 million to $165.70 million. For the next financial year, analysts anticipate that the company will post sales of $0.00 per share. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm had revenue of $41.30 million for the quarter, compared to the consensus estimate of $43.90 million. During the same quarter in the prior year, the business earned ($0.01) EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year.

Several research analysts have issued reports on VNDA shares. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Piper Jaffray Companies set a $26.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 19th. ValuEngine downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Finally, Oppenheimer set a $26.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $21.50.

Vanda Pharmaceuticals (NASDAQ VNDA) traded down $0.30 during trading hours on Tuesday, reaching $14.20. The company’s stock had a trading volume of 602,372 shares, compared to its average volume of 589,690. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99. The firm has a market cap of $642.46, a P/E ratio of -44.38 and a beta of 1.29.

In other news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the transaction, the insider now owns 1,031,848 shares of the company’s stock, valued at approximately $15,787,274.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO James Patrick Kelly sold 9,155 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the transaction, the chief financial officer now directly owns 144,721 shares in the company, valued at approximately $2,221,467.35. The disclosure for this sale can be found here. In the last three months, insiders sold 209,483 shares of company stock worth $3,205,205. 7.60% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of the company. California Public Employees Retirement System lifted its stake in shares of Vanda Pharmaceuticals by 3.8% in the 2nd quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock valued at $971,000 after purchasing an additional 2,200 shares during the period. Legal & General Group Plc lifted its stake in shares of Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the period. Bank of New York Mellon Corp raised its stake in Vanda Pharmaceuticals by 1.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 199,578 shares of the biopharmaceutical company’s stock worth $3,573,000 after buying an additional 3,305 shares during the period. Voya Investment Management LLC raised its stake in Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 4,605 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in Vanda Pharmaceuticals by 1.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 318,788 shares of the biopharmaceutical company’s stock worth $5,196,000 after buying an additional 4,986 shares during the period. 88.43% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $44.00 Million” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/16/vanda-pharmaceuticals-inc-vnda-expected-to-post-quarterly-sales-of-44-00-million-3.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.